Treatment of ischemic heart disease

Article written and reviewed by Dr Luca Moretti

The treatment of ischemic heart disease comprises a coordinated set of interventions aimed at modifying the atherosclerotic process, preventing thrombosis, reducing myocardial oxygen demand, increasing perfusion, controlling symptoms, and treating the consequences of ischemic injury. There is therefore no single “therapy for ischemia”: the treatment plan varies radically among chronic coronary syndrome, vasospastic or microvascular angina, acute coronary syndrome, myocardial infarction, ischemic cardiomyopathy, and heart failure.
The central principle is to distinguish disease-modifying therapies from predominantly symptomatic therapies. Reduction of atherogenic lipoproteins, smoking cessation, blood pressure and metabolic control, antithrombotic drugs when indicated, and certain cardiometabolic strategies reduce the risk of future events. Beta-blockers, calcium channel blockers, nitrates, ranolazine, and other antianginal drugs act mainly on symptoms and the ischemic threshold, with prognostic benefits that depend on the context.

Revascularization by PCI or CABG constitutes a third pillar. In acute coronary syndromes it can save myocardium and life; in chronic disease it is used for refractory symptoms or specific high-risk anatomies. It does not replace systemic therapy because a focal procedure eliminates neither the atherosclerotic burden nor the risk arising from untreated plaques.
Contemporary therapy must also be adapted to bleeding risk, renal function, the presence of diabetes, heart failure, atrial fibrillation, age, frailty, and preferences. Combining several drugs can produce a very substantial benefit, but increases the risk of interactions, hypotension, bradycardia, bleeding, and poor adherence. The quality of management therefore depends on integration, not simply on the sum of prescriptions.

Therapeutic goals and clinical phenotypes

In patients with chronic coronary syndrome, the goals are to prevent myocardial infarction and cardiovascular death, control angina, preserve functional capacity, and slow the progression of atherosclerosis. In acute coronary syndrome, the priority becomes rapidly identifying thrombosis and unstable ischemia, starting antithrombotic therapy, and achieving reperfusion when indicated.
In ischemic cardiomyopathy, in addition to preventing new events, ventricular dysfunction must be treated with guideline-directed heart failure therapy, surgical revascularization considered in selected patients, secondary mitral regurgitation corrected when appropriate, and sudden death prevented with an ICD or CRT according to specific criteria.

In patients with ANOCA/INOCA, treatment must be guided by the mechanism. A “non-obstructive” coronary angiogram does not mean absence of disease. Microvascular dysfunction and vasospasm require different drugs and strategies from epicardial stenosis; PCI is not indicated in the absence of a causative epicardial lesion.
The treatment plan must be reviewed over time. Angina may worsen because of disease progression, poor blood pressure control, anemia, tachyarrhythmia, or nonadherence; residual ischemic risk may remain high despite very low LDL-C because of Lp(a), diabetes, kidney disease, inflammation, or an advanced plaque burden.

Lifestyle and control of causal determinants

Smoking cessation is one of the most effective therapies. The benefit begins rapidly and grows over time. Intensive counseling, nicotine replacement, varenicline, or other evidence-based interventions should be used when appropriate. A generic recommendation without structured support is less effective.
Diet should follow a Mediterranean or equivalent pattern, rich in vegetables, legumes, whole grains, nuts, fish, and unsaturated fats. Trans fats, excess saturated fat, processed meats, added sugars, and sodium should be limited. The goal is not an immediate “antianginal” diet, but long-term modification of lipids, blood pressure, weight, and metabolism.

Regular physical activity improves functional capacity, blood pressure control, insulin sensitivity, and prognosis. After ACS or revascularization, supervised cardiac rehabilitation is recommended because it integrates exercise, adherence, education, nutrition, and psychological support. The program must be adapted to ventricular function and the ischemic threshold.
Obesity and visceral adiposity require active treatment. Weight loss, physical activity, nutrition, and, in appropriate patients, pharmacological therapy can improve the cardiovascular profile. Semaglutide 2.4 mg demonstrated a reduction in events in people with overweight or obesity and established cardiovascular disease without diabetes in the SELECT trial.

Reduction of atherogenic lipoproteins

Reducing LDL and apoB particles is the cornerstone of disease-modifying therapy. Genetic and randomized evidence demonstrates a causal and cumulative relationship. In patients with ASCVD, the greater the absolute risk and the more marked and sustained the LDL-C reduction, the greater the absolute benefit.
European guidelines maintain an LDL-C target of <55 mg/dL and a reduction of ≥50% from baseline for very-high-risk patients. The 2025 ESC/EAS update did not change these targets but strengthened the role of combination therapy and bempedoic acid in selected settings. The 2026 ACC/AHA guidelines reintroduced LDL-C and non-HDL-C targets and likewise use <55 mg/dL in patients with very-high-risk ASCVD.

First-line therapy is a high-intensity statin at the maximum tolerated dose. Atorvastatin 40-80 mg and rosuvastatin 20-40 mg are the principal high-intensity regimens. Statins increase LDL receptor expression, reduce the influx of atherogenic particles into the arterial wall, and shift plaque composition toward a less lipid-rich and inflammatory phenotype.
Statin intolerance must be assessed carefully, distinguishing truly drug-related symptoms from temporal associations. When possible, rechallenge, a different statin, alternate dosing, or combinations that permit a lower dose are used. Complete abandonment of lipid-lowering therapy in a patient with coronary artery disease significantly increases risk.

Ezetimibe inhibits NPC1L1 and reduces intestinal cholesterol absorption. IMPROVE-IT demonstrated that adding it to simvastatin after ACS further reduces events, confirming that an additional LDL reduction achieved by a mechanism other than statins produces benefit.
The anti-PCSK9 monoclonal antibodies evolocumab and alirocumab produce very large reductions in LDL-C. FOURIER and ODYSSEY OUTCOMES demonstrated reductions in events in high-risk patients already treated with statins. They can be added early when a patient remains far from the target or is at particularly high risk.

Inclisiran silences hepatic PCSK9 synthesis through siRNA and permits widely spaced administrations. It effectively reduces LDL-C; evidence for hard cardiovascular outcomes has not yet reached the same level as that for monoclonal antibodies. Its main potential advantage is treatment persistence.
Bempedoic acid inhibits ATP-citrate lyase and is activated predominantly in the liver. CLEAR Outcomes demonstrated a reduction in events in statin-intolerant patients. The 2025 ESC/EAS update recommends it when statins cannot be used to reach the target and considers its addition in uncontrolled high- or very-high-risk patients.

Lp(a) should be measured at least once in adulthood according to the 2026 ACC/AHA guidelines. High values increase risk even when LDL is controlled. At present, the main strategy is to intensify control of all modifiable factors; antisense drugs and siRNAs specific for Lp(a) have produced very large reductions, but definitive cardiovascular outcomes must guide any routine incorporation.
In patients with persistently elevated triglycerides despite statin therapy, icosapent ethyl demonstrated a reduction in events in REDUCE-IT. The benefit of the purified product must not be extended to generic omega-3 supplements or different mixtures that have not demonstrated the same outcome.

Antiplatelet therapy in chronic disease

In secondary prevention of coronary artery disease, low-dose aspirin remains the principal long-term antiplatelet agent in patients without an indication for anticoagulation and without contraindications. Clopidogrel may be used as an alternative and has a favorable profile in some settings.
After PCI for chronic coronary syndrome, a phase of dual antiplatelet therapy with aspirin and clopidogrel is used, with duration depending on ischemic and bleeding risk. With modern stents, many patients can be treated for shorter periods than in the past; complex procedures or high ischemic risk may justify different strategies.

The choice must not be based solely on fear of stent thrombosis. Intracranial or gastrointestinal hemorrhage can be equally serious. Risk scores, age, anemia, previous bleeding, CKD, the need for anticoagulation, and PCI complexity must be integrated.

Antithrombotic drugs in acute coronary syndromes

In ACS, DAPT with aspirin and a P2Y12 inhibitor is a fundamental part of therapy. The 2025 ACC/AHA guidelines recommend ticagrelor or prasugrel over clopidogrel in patients with STEMI or NSTE-ACS undergoing PCI when appropriate. The default strategy is approximately 12 months in patients who are not at high bleeding risk.
Prasugrel is contraindicated in patients with previous stroke or TIA and requires caution in advanced age or low body weight. Ticagrelor can cause dyspnea and bradycardia and interacts with specific drugs. Clopidogrel remains essential when the more potent P2Y12 inhibitors are unsuitable, in many strategies involving anticoagulation, and in patients at high bleeding risk.

DAPT duration may be shortened or followed by P2Y12 monotherapy in selected patients to reduce bleeding. The 2025 guidelines recognize the possibility of switching to ticagrelor monotherapy after at least one month in patients who have tolerated DAPT and for whom this strategy is appropriate.
During PCI, parenteral anticoagulants such as unfractionated heparin or, in specific settings, bivalirudin are used. GP IIb/IIIa inhibitors are not used routinely but may be employed as bailout therapy in the presence of a large thrombus or thrombotic complications.

Chronic anticoagulant therapy is not indicated for coronary atherosclerosis alone. Rivaroxaban 2.5 mg twice daily combined with aspirin constitutes a dual pathway inhibition strategy for selected patients with high-risk coronary or polyvascular disease and low bleeding risk, based on COMPASS.

Atrial fibrillation and the need for anticoagulation

When atrial fibrillation and PCI coexist, the combination of anticoagulant and antiplatelet agents must minimize the period of triple therapy. DOACs are generally preferred to vitamin K antagonists in eligible patients, and after a brief period with aspirin, anticoagulant plus clopidogrel is typically continued for the appropriate length of time.
The embolic risk of atrial fibrillation and the thrombotic risk of the stent are distinct. Eliminating the anticoagulant because the patient is taking DAPT exposes the patient to cardioembolic stroke; maintaining triple therapy long term causes excessive bleeding. Therapy must therefore be constructed around the indication for each drug.

Antianginal drugs: general principles

Symptomatic treatment must be personalized on the basis of heart rate, blood pressure, ventricular function, the mechanism of angina, and comorbidities. The 2024 ESC guidelines abandoned a universally rigid hierarchy between first- and second-line drugs in favor of a mechanism-guided approach.
The aim is to reduce episodes, raise the exercise threshold, and improve quality of life without causing hypotension, bradycardia, or interactions. If one drug is insufficient, classes with complementary mechanisms may be combined while avoiding hazardous combinations.

Beta-blockers

Beta-blockers reduce heart rate, contractility, and blood pressure, thereby lowering myocardial oxygen demand and prolonging diastole. They are particularly useful in exertional angina with a high heart rate and have specific prognostic indications in heart failure with reduced ejection fraction and in certain post-infarction settings.
The indefinite prognostic benefit after infarction with preserved ventricular function in the era of modern reperfusion is less certain than in the past. Contemporary guidelines therefore distinguish their symptomatic use and specific indications from automatic permanent prescription to every patient with coronary artery disease.

Bradycardia, atrioventricular block, hypotension, bronchospasm in susceptible individuals, fatigue, and sexual dysfunction may limit their use. Combination with verapamil or diltiazem requires caution because of the risk of excessive nodal and contractile depression.

Calcium channel blockers

Dihydropyridine calcium channel blockers, such as amlodipine, cause arterial vasodilation and reduce afterload without significant nodal depression. Verapamil and diltiazem instead reduce heart rate and atrioventricular conduction and can be highly effective for angina, but are generally avoided in HFrEF because of their negative inotropic effect.
In vasospastic angina, calcium channel blockers are the central therapy because they reduce epicardial vasoconstriction. Nonselective beta-blockers may worsen spasm and are not the treatment of choice in pure vasospasm.

Nitrates and nitric oxide donors

Sublingual nitroglycerin provides rapid relief of an anginal episode through venodilation, preload reduction, and coronary dilation. The patient must be taught to recognize prolonged or unusual symptoms that require urgent assessment and must not simply be treated with repeated doses at home.
Long-acting nitrates reduce symptoms but tolerance develops with continuous exposure; a nitrate-free interval is necessary. Combination with phosphodiesterase-5 inhibitors is contraindicated because of the risk of severe hypotension.

Ranolazine and other antianginal drugs

Ranolazine predominantly inhibits the late sodium current and reduces intracellular sodium and calcium overload, improving ischemic diastolic function. It has limited effects on heart rate and blood pressure and may be useful when bradycardia or hypotension prevents intensification of other classes.
It can prolong the QT interval and interacts with drugs metabolized through CYP3A. It must not be interpreted as antiarrhythmic therapy for preventing sudden death. Its principal benefit is symptomatic.

Ivabradine selectively reduces the If current in the sinus node and may be useful in specific patients with a high heart rate, sinus rhythm, and compatible indications, especially in heart failure. Nicorandil and trimetazidine are available in some countries and may be used in selected settings; availability and recommendations vary regionally.

ACE inhibitors, ARBs, and blood pressure control

ACE inhibitors or ARBs are recommended in patients with coronary artery disease and hypertension, diabetes, CKD, or ventricular dysfunction, and in other specific settings. The benefit derives from blood pressure control, neurohormonal modulation, and cardiorenal protection, not from an immediate antianginal effect.
The blood pressure target must be individualized, avoiding symptomatic hypotension or impaired perfusion. In patients with severe coronary disease, an excessive reduction in diastolic pressure could theoretically reduce coronary perfusion, but this does not justify deliberately maintaining hypertension.

Diabetes and cardiometabolic therapy

In type 2 diabetes with ASCVD, SGLT2 inhibitors and GLP-1 receptor agonists with demonstrated cardiovascular benefit have a role independent of simply reaching the HbA1c target. SGLT2 inhibitors are particularly valuable in heart failure and renal protection; GLP-1 agonists reduce atherosclerotic events and weight in several trials.
Intensive glycemic control must be individualized. Severe hypoglycemia can precipitate ischemia and arrhythmias; in older or frail patients, overly aggressive goals can be harmful. Therapy must therefore balance microvascular prevention, cardiovascular benefit, and safety.

Anti-inflammatory therapy

Demonstration that inflammation contributes causally to events has opened the possibility of treating residual inflammatory risk. CANTOS demonstrated that canakinumab reduces events without changing LDL-C, but cost, infection risk, and the absence of a routine cardiovascular indication have limited its use.
Low-dose colchicine reduced events in COLCOT and LoDoCo2. The 2024 ESC guidelines state that 0.5 mg/day should be considered in patients with chronic coronary syndrome and atherosclerosis, after assessing renal and hepatic function, interactions, and gastrointestinal tolerability.

Revascularization in chronic coronary syndrome

PCI or CABG is considered when angina persists despite medical therapy or when anatomy suggests a prognostic benefit. In intermediate stenoses, FFR or iFR helps avoid procedures on lesions that are not responsible for ischemia.
ISCHEMIA showed that in selected stable patients with moderate or severe ischemia, an initial invasive strategy does not universally reduce death or infarction compared with medical therapy, but improves symptom control in patients with angina. The choice must therefore be based on anatomy, symptoms, and risk, not solely on the presence of ischemia on testing.

CABG is preferred in specific complex anatomies, especially multivessel disease with diabetes and in many patients with left main disease. In selected ischemic cardiomyopathy with LVEF ≤35%, STICHES demonstrated a long-term survival benefit of surgery added to medical therapy.

Treatment of STEMI

STEMI requires immediate reperfusion. Primary PCI is preferred when available within the recommended time; when timely PCI cannot be achieved and there are no contraindications, fibrinolysis may be used in selected patients followed by transfer to a PCI center.
Aspirin is administered early, together with a P2Y12 inhibitor and anticoagulation according to the reperfusion strategy. A high-intensity statin is started as soon as possible. Oxygen is not administered routinely to normoxemic patients but is indicated in the presence of hypoxemia.

Nitrates may be used for symptoms and blood pressure control when hypotension, right ventricular infarction, and recent PDE5 inhibitor use are absent. Morphine is reserved for severe uncontrolled pain because it may slow the absorption of oral antiplatelet agents and must not be used automatically.
In stable patients with STEMI and multivessel disease, a complete revascularization strategy is recommended. In cardiogenic shock, however, the culprit lesion is treated urgently and immediate PCI of the other arteries is not routinely performed.

Treatment of NSTE-ACS and unstable angina

NSTE-ACS includes NSTEMI and, in the era of high-sensitivity troponins, a smaller proportion of unstable angina. Diagnosis and risk are defined through symptoms, ECG, troponin kinetics, ventricular function, and clinical scores.
Patients at intermediate or high risk are candidates for an invasive strategy during hospitalization, with revascularization when indicated. Hemodynamic instability, refractory pain, or life-threatening arrhythmias accelerate the timing. A selective invasive strategy may be appropriate in low-risk patients.

Antithrombotic therapy must balance ischemic and bleeding risk. Routine P2Y12 pretreatment before the anatomy is known is not appropriate in all patients, especially when early coronary angiography is possible and the need for CABG cannot be excluded.

Ischemic heart failure

When coronary artery disease has caused HFrEF, therapy must include the four pillars of heart failure treatment: an ARNI or ACE inhibitor/ARB, an evidence-based beta-blocker, a mineralocorticoid receptor antagonist, and an SGLT2 inhibitor, unless contraindicated. Diuretics are used to control congestion.
Titration need not necessarily wait until the maximum dose of one class is reached before the others are introduced. Early, sequential implementation of the four pillars produces a substantial prognostic benefit.

An ICD is indicated for secondary prevention after appropriate ventricular arrhythmias and for primary prevention in selected patients with persistently reduced LVEF despite therapy, respecting the required intervals after infarction and revascularization. CRT is indicated in specific patients with a wide QRS, especially left bundle branch block.

Ischemic mitral regurgitation and structural therapy

Secondary mitral regurgitation results from ventricular remodeling and leaflet tethering, not from primary valve disease. Initial therapy is optimization of heart failure treatment and, when indicated, revascularization.
In patients who remain symptomatic with severe MR despite optimal therapy, transcatheter edge-to-edge repair may be indicated in a selected phenotype based on COAPT evidence and guidelines. Selection requires assessment of severity, ventricular dimensions, pulmonary pressures, and valve anatomy.

Vasospastic angina

Epicardial vasospasm requires smoking cessation and calcium channel blockers as the main therapy. Long-acting nitrates may be added in patients with persistent symptoms. Invasive documentation with acetylcholine can define the mechanism in appropriate cases.
Nonselective beta-blockers may aggravate vasospasm through unopposed alpha-mediated vasoconstriction and are generally avoided in pure vasospasm. Coexisting atherosclerosis, microvascular dysfunction, or other indications may make management more complex.

Microvascular dysfunction and ANOCA/INOCA

Microvascular dysfunction may present with reduced CFR, increased microvascular resistance, or vasomotor abnormalities. Treatment depends on the endotype. Beta-blockers may be useful in some non-vasospastic forms; calcium channel blockers and nitrates are more appropriate when spasm predominates.
ACE inhibitors/ARBs, statins, and intensive risk-factor control may improve endothelial function. Ranolazine may reduce symptoms in subgroups, but the effect is variable. The most important point is to avoid classifying the patient as “noncardiac” solely because there is no obstructive stenosis.

Anemia, thyroid function, heart rate, and precipitating factors

Ischemia may be aggravated by extracoronary factors that increase demand or reduce oxygen transport. Anemia, tachyarrhythmias, fever, hyperthyroidism, hypoxemia, and severe hypertension can precipitate symptoms or a secondary myocardial infarction. Therapy requires correction of the precipitating factor in addition to management of coronary artery disease.
Transfusion in ACS must not be based on a single threshold independent of the clinical picture. The most recent evidence suggests a complex balance between the risk of anemia and transfusion risk; decisions and targets must be adapted to hemoglobin, ischemia, bleeding, and comorbidities.

Adherence, polypharmacy, and reasoned deprescribing

A scientifically perfect therapy that is not taken does not reduce risk. Follow-up must therefore assess actual adherence, costs, adverse effects, understanding, and regimen simplicity. Fixed-dose combinations may be useful when they improve persistence.
Deprescribing does not mean arbitrarily reducing prevention. It means eliminating drugs without a persistent indication, duplications, or therapies that produce more risk than benefit. One example is a beta-blocker maintained indefinitely without a specific indication in a patient with bradycardia and normal ventricular function.

Monitoring and follow-up

Monitoring includes symptoms, blood pressure, heart rate, lipid profile, renal function, electrolytes, HbA1c when appropriate, and drug tolerability. After lipid-lowering therapy is started or intensified, the profile is reassessed to verify response and adherence.
Ischemia testing or imaging should not be repeated routinely in stable asymptomatic patients without a question capable of changing management. New symptoms, reduced functional capacity, heart failure, or arrhythmias instead require targeted reassessment.

Therapy must be updated as evidence evolves. Ischemic heart disease is a field in which guidelines, drugs, and antithrombotic strategies change rapidly; management of high-risk patients therefore requires periodic review of the treatment plan, not indefinite repetition of the original prescription.

Prognosis and residual risk

Despite optimal therapy, risk does not become zero. Accumulated plaque burden, myocardial scars, Lp(a), kidney disease, diabetes, inflammation, and polyvascular disease contribute to residual risk. The realistic goal is to substantially reduce the probability of new events and preserve function and quality of life.
The absolute benefit of therapy is greater in higher-risk patients. A 50 mg/dL LDL reduction or the addition of an antithrombotic agent may produce very different benefits in a person with multivessel disease and diabetes than in a young person at low risk; this is why treatment must be stratified.

Contemporary therapy for ischemic heart disease is therefore multidimensional: it reduces the atherosclerotic substrate, prevents thrombosis, modulates oxygen demand and supply, treats heart failure and arrhythmias, revascularizes when necessary, and addresses behavioral and metabolic determinants. Success derives more from the consistency of these interventions over time than from a single drug or procedure.

Selection and intensification of lipid-lowering therapy

Lipid-lowering therapy must be planned according to the distance from target. If a patient with ACS has an LDL-C of 150 mg/dL, a high-intensity statin alone is unlikely to bring it below 55 mg/dL. In this setting, early initiation of a statin plus ezetimibe combination avoids months of residual exposure and reduces the risk that therapy remains chronically insufficient.
The 2025 ACC/AHA ACS guidelines recommend a high-intensity statin for all patients and permit simultaneous initiation of ezetimibe. If the patient is already taking the maximum tolerated statin and LDL-C remains ≥70 mg/dL, adding nonstatin therapy is recommended; in the 55-69 mg/dL range, further intensification is reasonable in high-risk patients.

Monitoring after therapy is started or modified serves to verify biological response and adherence. A reduction much smaller than expected may result from nonadherence, an incorrect dose, interactions, or familial hypercholesterolemia. These causes must be excluded before attributing the poor response to pharmacological “resistance.”
Achieving very low LDL-C values with PCSK9 inhibitors has not shown a harm signal in large trials that would justify automatic discontinuation. In patients at extremely high risk, the strategy is therefore directed toward maintaining an intense and sustained reduction.

Bleeding risk and personalization of DAPT

The duration of antithrombotic therapy depends on the balance between ischemic risk and bleeding risk. Anemia, previous bleeding, thrombocytopenia, CKD, cancer, chronic anticoagulant use, and frailty increase hemorrhagic risk. The ARC-HBR definition provides standardized criteria useful in practice and trials.
Complex PCI with numerous stents, left main involvement, two-stent bifurcations, or previous stent thrombosis may increase ischemic risk and make very early DAPT discontinuation less attractive. Conversely, a patient with recent bleeding and simple PCI may benefit from an abbreviated strategy.

Proton pump inhibitors are recommended in patients at increased gastrointestinal risk who receive DAPT. Gastric protection does not eliminate overall bleeding risk but reduces an important and often preventable component.
De-escalation from prasugrel or ticagrelor to clopidogrel may be used in selected settings, either unguided or test-guided according to the strategy. It must not be performed casually during the first days of extremely high thrombotic risk without considering the clinical context.

Blood pressure and coronary perfusion

Hypertension accelerates atherosclerosis and increases myocardial demand and the risk of stroke and heart failure. Blood pressure treatment is therefore part of coronary therapy. ACE inhibitors, ARBs, beta-blockers, calcium channel blockers, diuretics, and mineralocorticoid antagonists are selected according to comorbidities.
The concept of a diastolic blood pressure J-curve requires interpretation. Very low pressures may be associated with poorer coronary perfusion, especially with severe stenoses, but often also reflect age, arterial stiffness, and comorbidities. Intentionally maintaining high blood pressure is not appropriate; symptomatic hypotension should instead be avoided and therapy titrated individually.

In patients with angina and hypertension, drugs that simultaneously lower blood pressure and oxygen demand may offer a dual benefit. In patients who are already hypotensive, ranolazine or strategies with less hemodynamic effect may be more suitable.

Chronic kidney disease

CKD identifies a phenotype at high risk of ischemic events and bleeding. Statin therapy remains fundamental in nondialysis stages, whereas the effect of initiating statins in dialysis is less favorable than in earlier stages. Treatment must also consider the dose and safety of renally eliminated drugs.
SGLT2 inhibitors have transformed cardiorenal protection and are indicated in many populations with CKD and heart failure regardless of the presence of diabetes, according to their specific indications. The initial eGFR reduction after initiation frequently represents an expected hemodynamic effect and does not automatically signify progressive kidney injury.

The choice and duration of antithrombotic drugs require particular caution. Advanced CKD simultaneously increases thrombosis and bleeding; doses of DOACs and parenteral anticoagulants must be adapted to renal function.

Post-infarction: prevention of remodeling and neurohormonal therapy

After infarction, myocardial loss can activate the renin-angiotensin-aldosterone and sympathetic systems, promoting dilation and remodeling. In patients with ventricular dysfunction, heart failure, diabetes, or other indications, ACE inhibitors or ARBs should be started early when hemodynamically tolerated.
Mineralocorticoid receptor antagonists are indicated after infarction in selected patients with reduced LVEF and heart failure or diabetes, in the absence of hyperkalemia or severe renal failure. Monitoring potassium and creatinine is essential.

Ventricular function must be reassessed after an appropriate period of therapy and revascularization before deciding on an ICD for primary prevention, because some dysfunction may recover. Implantation too soon after infarction has not demonstrated the same benefit as a deferred strategy based on persistent risk.

Analgesia, oxygen, and drugs to avoid in ACS

Oxygen should be administered in the presence of hypoxemia or respiratory distress, not routinely to every patient with chest pain and normal oxygen saturation. Hyperoxia has not demonstrated benefit and can cause coronary vasoconstriction.
Morphine is used when ischemic pain is severe and persistent despite nitrates and other appropriate measures. It can delay the absorption of oral P2Y12 inhibitors and should therefore be reserved for a genuine analgesic need.

Nonaspirin NSAIDs increase cardiovascular risk and should be avoided or used at the lowest possible dose and for the shortest duration in patients with coronary artery disease. Some selective COX-2 inhibitors and diclofenac have a particularly unfavorable cardiovascular profile.

Treatment of refractory angina

When angina persists despite multiple drug classes and no further revascularization is possible, the diagnosis must be reconsidered. Microvascular ischemia, vasospasm, anemia, hypertension, musculoskeletal pain, and anxiety may coexist and require different treatments.
The coronary sinus reducer may be considered in selected patients with refractory angina and ischemia in the left coronary territory who are not candidates for conventional revascularization. Studies have demonstrated improvements in symptoms and quality of life; there is no equivalent evidence of reduced mortality.

Specialist management of refractory angina integrates rehabilitation, medication optimization, management of mood disorders, and selected interventional techniques. Reducing the symptom burden is a legitimate clinical goal even when prognosis is not directly modified.

Advanced age, frailty, and deprescribing

In older adults, the absolute risk of events is high, so preventive therapies can offer substantial benefit. However, frailty, falls, anemia, renal failure, orthostatic hypotension, and polypharmacy increase adverse effects. Age alone is not a reason to withhold statins, antiplatelet agents, or revascularization.
Reasoned deprescribing should target drugs without a persistent indication, not effective prognostic treatments. A long-acting nitrate may be reduced if angina has resolved after revascularization; a statin for secondary prevention should not be stopped simply because the patient has passed a certain age.

Blood pressure and glycemic goals may be less aggressive in patients with severe frailty or limited life expectancy. The priority may shift toward preventing symptoms, falls, hypoglycemia, and hospitalizations.

Mental health, sleep, and adherence

Depression and anxiety are common after infarction and are associated with poorer quality of life and lower adherence. Screening and treatment of mood disorders are part of cardiac rehabilitation. Antidepressants must be selected with consideration of their cardiovascular profile and interactions.
Obstructive sleep apnea is common in patients with obesity, hypertension, and atrial fibrillation. Treatment improves symptoms and blood pressure in selected patients, but CPAP must not be presented as a specific therapy certain to reduce coronary events in every patient.

Adherence can be improved by reducing the number of daily administrations, using fixed-dose combinations, explaining goals and possible adverse effects, and addressing costs and social barriers. Shared decision-making is not decorative: it increases the likelihood that the patient will maintain therapy over time.

Sexual activity and erectile dysfunction

Sexual activity causes a moderate increase in cardiovascular demand and is generally safe in stable patients with good functional capacity. Risk increases in patients with unstable angina, uncontrolled heart failure, or severe arrhythmias and requires stabilization before resumption.
PDE5 inhibitors can be used in many patients with stable coronary artery disease, but are absolutely incompatible with nitrates because of the risk of severe hypotension; this point must be discussed explicitly, because the patient may take nitrates as needed and not consider them chronic therapy.

Vaccination and infection prevention

Respiratory infections can precipitate infarction and heart failure through inflammation, hypoxia, and increased demand. Annual influenza vaccination is recommended in patients with cardiovascular disease and represents an often underused secondary-prevention measure.
Other vaccinations are indicated according to age, comorbidities, and national programs. Their cardiovascular rationale is primarily the prevention of infections capable of destabilizing vulnerable patients, not a direct effect on plaque.

Polyvascular disease and intensified antithrombotic therapy

The coexistence of coronary artery disease with peripheral arterial or carotid disease identifies a high atherosclerotic burden. In these patients, the absolute benefit of intensive lipid-lowering and antithrombotic therapies may be greater, but bleeding risk also increases.
The COMPASS strategy of rivaroxaban 2.5 mg twice daily plus aspirin reduces events in selected patients with stable coronary artery disease or PAD, at the cost of more major bleeding. It is appropriate when ischemic risk is high and bleeding risk is not, not as an automatic prescription for every patient with CAD.

Perioperative management of antithrombotic therapy

Noncardiac surgery requires management of the risks of stent thrombosis and bleeding. Timing after PCI, type of surgery, and the possibility of continuing aspirin determine the strategy. Stopping a P2Y12 inhibitor early after recent PCI may be dangerous, while continuing DAPT during surgery with a high bleeding risk may be equally problematic.
The decision should involve the cardiologist, surgeon, and anesthesiologist in high-risk cases. Bridging strategies with intravenous drugs have very selective indications and do not replace proper planning of surgical timing.

Measuring quality of care

The quality of coronary treatment can be measured through the percentage of patients with LDL at target, smoking cessation, appropriate prescription of antithrombotic drugs, access to rehabilitation, blood pressure control, and reperfusion times in STEMI; these indicators reflect processes concretely associated with outcomes.
A center with high technical capability but poor adherence to secondary prevention does not provide complete coronary care. Likewise, excellent lipid targets do not offset systematic delays in infarct reperfusion. Ischemic heart disease requires quality throughout the entire care pathway.

Integrated pharmacology of angina and choice of combinations

Combinations of antianginal drugs must respect the patient's physiology. A person with a heart rate of 85 bpm and high blood pressure may benefit from a beta-blocker; a patient with a heart rate of 52 bpm and blood pressure of 100/60 mmHg will not tolerate the same intensification and may be better suited to ranolazine or a revascularization strategy if ischemia is documented.
Combining a beta-blocker with a dihydropyridine such as amlodipine is often effective because it couples reduced demand with vasodilation. Combination with verapamil or diltiazem requires caution because of the risk of bradycardia, AV block, and contractile depression. Verapamil and diltiazem are generally avoided in HFrEF.

Long-acting nitrates may be added when symptoms persist, but must be scheduled with a nitrate-free interval to limit tolerance. Headache is common and may reduce adherence. Hypotension is particularly relevant when nitrates are combined with other vasodilators.
Ranolazine is useful when blood pressure and heart rate limit other drugs, but requires attention to the QT interval and CYP3A interactions. In a patient taking potent CYP3A inhibitors, exposure may increase significantly. Medication review is therefore part of antianginal prescribing.

Lipid-lowering therapy in ACS: why start during hospitalization

The period immediately following ACS is characterized by a very high risk of recurrence. Starting intensive LDL reduction during hospitalization has biological and organizational advantages: it reduces exposure early and increases the likelihood that the patient will be discharged on adequate therapy.
An excessively slow stepwise strategy may be inefficient. If the reduction expected from a statin cannot achieve the target, adding ezetimibe at discharge is rational. In patients whose LDL remains very high despite therapy or who have recurrent events, PCSK9 inhibitors may be introduced early according to indications and access.

The lipid profile should be measured early during ACS because LDL-C may fall in the following days with the acute-phase response. The initial value helps estimate pre-event exposure and the required percentage reduction.

Hypertriglyceridemia and remnants

Elevated triglycerides often reflect an increase in triglyceride-rich lipoproteins and their remnants, apoB-containing particles that carry cholesterol and participate in atherogenesis. First-line therapy remains correction of obesity, diabetes, alcohol use, and diet, together with a statin for atherosclerotic risk.
Icosapent ethyl demonstrated a reduction in events in REDUCE-IT among statin-treated patients with elevated triglycerides. The mechanism of benefit cannot be attributed solely to triglyceride reduction, and the result cannot be generalized to over-the-counter products or mixed EPA/DHA formulations.

Extremely high triglyceride values require a different approach because the immediate risk includes pancreatitis. In this setting, a very-low-fat diet, correction of secondary causes, and specific drugs may take priority, while coronary prevention remains a parallel goal.

Lipoprotein(a) and residual risk

Lp(a) increases the risk of coronary artery disease and calcific aortic stenosis through atherogenic and proinflammatory components. Its level is predominantly genetic and is only minimally modified by diet and exercise; therefore, a single measurement in adulthood is generally sufficient for initial stratification.
Statins may modestly increase Lp(a) but remain essential because they substantially reduce risk through LDL. Anti-PCSK9 antibodies moderately reduce Lp(a) in addition to LDL. Apheresis is used in highly selected cases in healthcare systems where it is indicated.

Specific antisense drugs and siRNAs have demonstrated Lp(a) reductions greater than those of traditional drugs. Until definitive evidence of event reduction and regulatory indications are available, elevated Lp(a) should primarily prompt aggressive reduction of all other modifiable risks.

Therapy in patients with previous CABG or PCI

After revascularization, secondary prevention must be at least as intensive. A stent does not protect against plaques in other segments; a bypass does not halt progression of native coronary disease or degeneration of vein grafts.
After CABG, aspirin and a statin are fundamental for reducing events and preserving grafts. Blood pressure, diabetes, and smoking must be controlled intensively. The presence of a patent internal mammary graft does not justify relaxing lipid targets.

After PCI, antithrombotic therapy proceeds through the DAPT phase and then long-term prevention. Duration must be reassessed if new bleeding occurs, anticoagulation becomes necessary, or surgery is required. Decisions made at discharge are not immutable.

Therapy after infarction with preserved ventricular function

In post-infarction patients with preserved LVEF, secondary prevention remains intensive, but some historical therapies require reassessment. Aspirin, lipid-lowering therapy, risk-factor control, and rehabilitation are central; beta-blockers are used for angina, hypertension, arrhythmias, or other indications, but their indefinite prognostic benefit in the absence of ventricular dysfunction is less certain in the modern era.
ACE inhibitors or ARBs are particularly indicated in the presence of hypertension, diabetes, CKD, ventricular dysfunction, or a large infarction. Not every normotensive patient with completely normal function needs the same intensity of neurohormonal therapy.

The treatment decision must therefore avoid fossilization of the post-infarction protocol: drugs are maintained when they have a persistent indication and reviewed when the clinical context changes.

Treatment of heart failure with mildly reduced or preserved ejection fraction

Coronary artery disease may coexist with HFrEF or HFpEF, in which ischemia is only one component of the phenotype. SGLT2 inhibitors have demonstrated a reduction in heart failure hospitalizations across the entire ejection-fraction spectrum and represent an important therapy when indicated.
Diuretics are used for congestion regardless of ejection fraction. Blood pressure, obesity, atrial fibrillation, diabetes, and CKD must be treated aggressively. Revascularization of a stenosis must be indicated because of ischemia or anatomy, not simply because the patient has HFpEF.

Arrhythmias and ischemic therapy

Acute ischemia can cause premature beats, ventricular tachycardia, ventricular fibrillation, or conduction block. First-line therapy is reperfusion and correction of the acute substrate, together with correction of potassium, magnesium, and hypoxia. Amiodarone or other antiarrhythmic drugs are used in the appropriate setting but do not replace revascularization.
With a post-infarction scar, monomorphic VT may persist even when the coronary arteries have been completely revascularized. ICDs and ablation are specific tools for arrhythmic risk. It is therefore incorrect to regard PCI as sufficient treatment for scar-related ventricular tachycardia.

Atrial fibrillation requires rate or rhythm control and anticoagulation according to embolic risk. When recent PCI coexists, the antithrombotic regimen must coordinate both indications while minimizing triple therapy.

Metabolic drugs and obesity beyond diabetes

Cardiovascular treatment of obesity is evolving rapidly. GLP-1 agonists and incretin-based molecules produce substantial weight loss and modify blood pressure, blood glucose, and inflammation. The SELECT trial demonstrated cardiovascular benefit of semaglutide 2.4 mg in patients with cardiovascular disease and obesity or overweight without diabetes.
These drugs do not replace statins, antiplatelet agents, or blood pressure control. They should be understood as a new component of cardiometabolic risk reduction in appropriate phenotypes, with attention to gastrointestinal tolerability, cholelithiasis, and loss of lean mass.

Follow-up after ACS: transition from hospital to community care

The risk of therapeutic errors is high during the transition after discharge. The patient must receive a clear plan specifying DAPT duration, LDL and blood pressure targets, physical activity guidance, warning signs, and follow-up appointments. A complex prescription without explanation leads to early discontinuation.
Early reassessment makes it possible to check symptoms, adherence, and tolerability and to intensify lipid-lowering therapy if the target has not been reached. Cardiac rehabilitation should be arranged before discharge because late referral reduces participation.

Smoking cessation must be addressed immediately, with pharmacological therapy if necessary. Every hospitalization for ACS represents a period of high motivation in which structured interventions can produce lasting change.

Signs of instability requiring urgent reassessment

A patient with chronic coronary artery disease must know that new pain at rest, a rapid increase in episode frequency, syncope, sudden dyspnea, or prolonged symptoms represent a change in phenotype. Simply increasing the nitrate or waiting for the scheduled visit can be dangerous.
Outpatient treatment of ischemic heart disease must therefore include a safety strategy: symptom recognition, correct use of sublingual nitrate, and activation of emergency services when pain does not resolve rapidly or differs from usual.

Therapy and long-term prognosis

Risk reduction is cumulative, just as causal exposure has been. Maintaining low LDL, not smoking, controlling blood pressure and diabetes, and taking therapy correctly for years produces greater benefit than a brief period of intensive treatment followed by abandonment.
The concept of residual risk must not generate nihilism. Even when Lp(a), scar, or plaque burden remain, reducing modifiable factors continues to produce benefit. Residual risk describes what remains after therapy, not the ineffectiveness of therapy itself.

The best prognosis results from integrating early treatment of acute events, appropriate revascularization, intensive disease-modifying therapy, symptom control, and rehabilitation. Each component acts at a different level of the disease, and none can completely replace the others.

Risk stratification and intensity of disease-modifying therapy

Ischemic heart disease is not a binary condition in which all patients require the same treatment intensity. Residual risk varies according to atherosclerotic burden, the number of territories involved, previous infarction, ventricular function, diabetes, kidney disease, peripheral arterial disease, Lp(a), inflammation, smoking, and control of causal factors. The modern strategy must therefore use the same diagnosis to construct treatment plans of different intensity, avoiding both undertreatment of the extremely high-risk patient and unnecessary polypharmacy in the lower-risk individual.
Previous infarction, multivessel coronary artery disease, polyvascular disease, left ventricular dysfunction, and chronic kidney disease identify categories in which the absolute benefit of further reducing LDL-C, blood pressure, thrombotic events, and heart failure is greater. In these patients it is particularly important to reach targets rapidly and not wait months between treatment changes when it is already predictable that a single class will be insufficient.

The distinction between secondary prevention and symptomatic treatment must be explicit. Statins, ezetimibe, anti-PCSK9 drugs, smoking cessation, blood pressure control, and many cardiometabolic therapies modify event risk. Beta-blockers, calcium channel blockers, nitrates, and ranolazine are instead used mainly to reduce symptomatic ischemia and improve quality of life, except for specific independent prognostic indications. Confusing these goals can lead to intensifying antianginal drugs without correcting the principal atherothrombotic risk.
Therapy must be reassessed after every major event. A new infarction despite apparently controlled LDL-C requires verification of adherence, values actually achieved, Lp(a), diabetes, smoking, inflammatory disease, and the possibility of a nonatherothrombotic mechanism. Recurrent ischemia does not necessarily imply “failure” of the statin or antiplatelet agent, but indicates that overall residual risk remains high and must be separated into its determinants.

Documented non-obstructive coronary artery disease on CCTA does not mean zero risk. A diffuse plaque burden, even without critical stenosis, identifies a patient in whom prevention may be intensified before an event occurs. The potential benefit derives from early modification of cumulative exposure to lipoproteins and other causal factors, not from waiting until disease becomes hemodynamically significant.

Advanced lipid-lowering therapy and residual atherogenic risk

The fundamental principle of lipid-lowering therapy is that cardiovascular benefit depends mainly on the absolute reduction in exposure to atherogenic particles over time. An LDL-C reduction achieved early and maintained for years produces a greater cumulative benefit than the same reduction started late. In patients with overt coronary disease, this principle justifies an intensive approach from the outset and close monitoring until the target is reached.
The lipid profile must be interpreted beyond LDL-C alone. Non-HDL-C reflects the cholesterol contained in all apoB particles, while apoB directly approximates the number of atherogenic particles. In patients with diabetes, obesity, metabolic syndrome, or hypertriglyceridemia, LDL-C and apoB may be discordant because particles carry different amounts of cholesterol. In these settings, apoB and non-HDL-C can provide a more complete assessment of residual risk.

The choice of combination must be proportional to the distance from target. A high-intensity statin can reduce LDL-C by about half, ezetimibe adds a further reduction, and anti-PCSK9 drugs can produce very large decreases. In a patient with an extremely high initial LDL-C, waiting through long sequential intervals between monotherapy and combination therapy creates months of avoidable risk. The most recent guidelines therefore favor an early combination when the target cannot plausibly be achieved with one drug.
The safety of very low LDL-C values has been assessed in large randomized programs. In high-risk patients treated with anti-PCSK9 drugs, no signal has emerged that would justify automatically stopping therapy solely because LDL-C reaches very low values, provided treatment is clinically indicated and well tolerated. Attention should focus on actual adverse effects, adherence, cost, and absolute benefit, not on an unsupported arbitrary threshold.

Lp(a) represents an important component of genetically determined residual risk. A high concentration is not normalized by lifestyle and may explain premature events in families in which LDL-C does not appear exceptional. Until specific therapies with definitively demonstrated outcome benefits are available, management consists mainly of aggressively lowering LDL-C and controlling other modifiable factors. Anti-PCSK9 drugs also reduce Lp(a) moderately, but their benefit cannot be attributed solely to this effect.
Hypertriglyceridemia must be interpreted as a marker of altered metabolism of triglyceride-rich lipoproteins and their remnants. Control of apoB particles and secondary causes, including uncontrolled diabetes, alcohol, obesity, and drugs, remains the priority. Icosapent ethyl has specific evidence for event reduction in selected patients with elevated triglycerides despite statin therapy; this evidence cannot be transferred to any omega-3 supplement.

Antithrombotic precision: ischemia, bleeding, and anticoagulation

Antithrombotic therapy must balance two risks that frequently increase in the same patient: ischemia and bleeding. Advanced age, kidney disease, anemia, and frailty increase bleeding risk but often coexist with diffuse coronary artery disease, diabetes, or previous events that increase ischemic risk. The problem cannot be solved with the same standard duration for everyone; it requires a temporal strategy in which drug intensity and number change as risk evolves.
After ACS treated with PCI, approximately twelve months of DAPT remains the reference strategy in patients without high bleeding risk. Shortening DAPT, de-escalating from a potent P2Y12 inhibitor to clopidogrel, or switching to P2Y12 monotherapy is appropriate in selected patients; these strategies are not equivalent in every situation: timing, PCI complexity, previous thrombosis, bleeding risk, and adherence must guide the choice.

The ARC-HBR criteria provide a standardized definition of high bleeding risk after PCI and include conditions such as significant anemia, thrombocytopenia, advanced kidney disease, previous hemorrhage, chronic anticoagulation, and other comorbidities. Their principal value is to make systematic an assessment that might otherwise be intuitive. Even in an HBR patient, however, treatment duration must consider any extreme risk of stent thrombosis or recurrent ischemia.
In patients with atrial fibrillation and PCI, combining an oral anticoagulant with dual antiplatelet therapy greatly increases bleeding risk. DOAC trials have supported strategies that minimize triple-therapy duration and continue an anticoagulant plus a single P2Y12 inhibitor, generally clopidogrel, for a period defined by ischemic risk. Subsequently, oral anticoagulant monotherapy often becomes sufficient in stable patients. The exact duration must be adapted to thrombotic risk, PCI complexity, and bleeding risk.

Proton pump inhibition is appropriate in patients at high risk of gastrointestinal bleeding who are treated with DAPT or antithrombotic combinations. Prevention also includes correcting anemia, treating known gastrointestinal lesions, controlling blood pressure, and reducing unnecessary NSAID use. Antithrombotic safety therefore also depends on interventions that are not directly cardiovascular.
Dual pathway inhibition with aspirin and very-low-dose rivaroxaban can reduce events in selected patients with stable high-risk coronary or peripheral disease and low bleeding risk. It is not equivalent to full-dose anticoagulation for atrial fibrillation and must not replace an anticoagulant dose when there is a formal indication for prevention of cardioembolic stroke.

Rational selection of antianginal therapy

Antianginal therapy must be selected on the basis of the individual patient's pathophysiology and hemodynamics. Heart rate, blood pressure, ventricular function, atrioventricular conduction, the presence of vasospasm, microvascular dysfunction, and comorbidities determine which drugs are appropriate. There is no absolute hierarchy valid for every patient, and combining drugs with complementary mechanisms often permits better symptom control with fewer adverse effects than maximizing a single class.
Beta-blockers reduce heart rate, contractility, and blood pressure and prolong diastolic time. They are particularly useful when angina is associated with tachycardia, recent previous infarction in specific settings, ventricular dysfunction, or arrhythmias. Conversely, they may worsen severe bronchospasm, bradycardia, or conduction block and, in patients with pure vasospasm, some nonvasodilating beta-blockers may theoretically favor alpha-adrenergic predominance and are not the first choice.

Dihydropyridine calcium channel blockers reduce blood pressure and vascular resistance without significantly depressing AV conduction, whereas verapamil and diltiazem also reduce heart rate and contractility; the latter should be avoided or used with great caution in HFrEF because of their negative inotropic effect. In epicardial vasospasm, calcium channel blockers are a reference therapy and may be combined with long-acting nitrates when necessary.
Nitrates reduce preload and dilate the epicardial coronary arteries, with a rapid symptomatic effect in sublingual formulations. Chronic use requires a nitrate-free interval to limit tolerance. Combination with phosphodiesterase-5 inhibitors is contraindicated because of the risk of severe hypotension. Response to a nitrate is not diagnostic of ischemia because esophageal pain may also improve.

Ranolazine reduces the late sodium current and may improve symptoms with relatively modest effects on blood pressure and heart rate, a useful characteristic in patients limited by hypotension or bradycardia. The risk of QT prolongation and metabolic interactions must be considered. Ivabradine is useful mainly in patients with HFrEF in sinus rhythm who meet specific criteria and must not be used as a universal antianginal drug.
In patients with persistent angina despite therapy, the next question is not simply which drug to add. Adherence, diagnosis, the presence of treatable epicardial ischemia, vasospasm, microvascular dysfunction, anemia, tachyarrhythmia, hypertension, or extracardiac conditions must be assessed. Refractory angina should be diagnosed only after these determinants have been identified and treated.

Post-infarction treatment and prevention of remodeling

After infarction, therapy must simultaneously prevent new atherothrombotic events and limit ventricular remodeling. Patients with reduced LVEF or signs of heart failure benefit from early introduction of appropriate neurohormonal therapies, compatible with blood pressure, renal function, and hemodynamic stability. Initial echocardiographic assessment and reassessment after a period of optimized therapy are fundamental for prognosis and any indication for an ICD.
ACE inhibitors or ARBs have an established role after infarction in patients with ventricular dysfunction, hypertension, diabetes, or other indications. In patients with symptomatic HFrEF, sacubitril/valsartan replaces the ACE inhibitor or ARB when appropriate according to heart failure guidelines. Initiation must observe the washout interval after an ACE inhibitor to reduce the risk of angioedema.

Mineralocorticoid receptor antagonists reduce mortality and hospitalization in appropriate patients with HFrEF and after infarction with ventricular dysfunction and heart failure or diabetes, provided renal function and potassium permit their use. The risk of hyperkalemia requires close monitoring after initiation and dose increases.
SGLT2 inhibitors have become one of the four fundamental classes for HFrEF, regardless of the presence of diabetes. The benefit for heart failure appears early and is partly independent of glucose lowering. Management must consider volume depletion, genital infections, the risk of ketoacidosis, and temporary discontinuation during prolonged fasting or severe acute illness.

Prevention of sudden death requires an assessment distinct from revascularization. An ICD for primary prevention is indicated in selected patients with persistently reduced LVEF despite optimized therapy and after an appropriate interval from infarction and revascularization, because ventricular function may recover in the months following the event. Implantation too early after infarction has not demonstrated the same benefit for total mortality.
CRT is indicated in patients with HFrEF, prolonged QRS, and specific electrocardiographic characteristics, especially left bundle branch block, when symptoms persist despite medical therapy. The benefit derives from correction of dyssynchrony, not from ischemic heart disease itself. Extensive scar may reduce the response, especially if the left ventricular lead is placed in a scarred region.

Special populations and high-impact comorbidities

In patients with chronic kidney disease, ischemic and bleeding risks increase simultaneously. Statins and other lipid-lowering therapies remain fundamental in nonterminal stages, but the choice and dosing of numerous drugs require adjustment to renal function. ACE inhibitors, ARBs, mineralocorticoid antagonists, and SGLT2 inhibitors can provide cardiovascular and renal benefits, but require monitoring of creatinine, potassium, blood pressure, and volume.
In older patients, frailty is often more informative than chronological age. Falls, cognitive impairment, polypharmacy, sarcopenia, malnutrition, and bleeding risk may alter the benefit-risk ratio of aggressive therapies; this does not justify systematic undertreatment: drugs with a prognostic benefit should be used when tolerated, but dose, goals, and regimen complexity must be adapted to the actual ability to manage them.

Women with ischemic heart disease have historically been underrepresented in many trials and may present more frequently with ANOCA/INOCA and nonclassic symptoms. Treatment of documented atherosclerotic disease must not be less intensive on the basis of sex. In women of childbearing potential, possible pregnancy, the teratogenicity of some drugs, and the need for preconception planning must be considered.
Polyvascular disease, with coronary and peripheral or cerebrovascular involvement, identifies a high atherosclerotic burden; these patients obtain a particularly important absolute benefit from intensive LDL-C reduction and may be candidates for more intensive antithrombotic strategies when bleeding risk is acceptable. The presence of peripheral arterial disease should also prompt smoking cessation, structured exercise, and foot care in people with diabetes.

In patients with chronic inflammatory diseases, HIV, or other conditions associated with atherosclerotic risk, therapy must integrate control of the underlying disease and drug interactions. Some immunosuppressants, antiretrovirals, or cancer therapies alter lipid metabolism, blood pressure, QT interval, or ventricular function and may require coordination between the cardiologist and the specialist managing the primary disease.

Refractory angina, nonconventional therapies, and quality of life

Refractory angina is generally defined as persistent chronic ischemic symptoms despite optimal medical therapy and the absence of further effective conventional revascularization options. Before using this label, anatomy, physiology, adherence, differential diagnosis, and microvascular or vasospastic mechanisms must be reassessed. Some apparently “no-option” patients may become treatable after reassessment at a center experienced in CTO or complex surgery.
Therapy must include rational optimization of antianginal drugs, rehabilitation, management of anxiety and mood, and treatment of factors that increase myocardial demand. Chronic limitation can produce deconditioning and fear of activity, creating a vicious cycle in which functional capacity worsens even without anatomical progression. Structured exercise programs may therefore have a role even in patients with persistent symptoms, provided safety has been established.

The coronary sinus reducer creates a controlled stenosis of the coronary sinus with the aim of modifying subendocardial flow distribution. Randomized studies have shown symptom improvement in selected patients with refractory angina who are not candidates for revascularization. The device does not treat atherosclerosis and does not replace secondary prevention; its use remains restricted to selected centers and patients.
Spinal cord stimulation and other neuromodulation strategies have been used in selected cases to reduce the perception of angina and improve quality of life. The evidence is less robust than for standard therapies, and their use requires expert centers. Pain reduction must not mask a new acute coronary syndrome, so the patient must receive precise instructions regarding changes in the symptom pattern.

Stem-cell therapy, gene angiogenesis, and numerous biological approaches have produced experimental or preliminary results but do not constitute standard treatment for ischemic heart disease. Distinguishing promising research from validated treatment is particularly important in this field, where patients with severe symptoms may be vulnerable to therapeutic offerings unsupported by reliable clinical outcomes.

Adherence, vaccinations, psychosocial factors, and continuity of care

Nonadherence is a common cause of apparent treatment resistance. Complex regimens, costs, adverse effects, poor understanding of benefit, and depression may reduce persistence. Periodic medication review must therefore include specific questions about doses actually taken, interruptions, self-medication, and practical difficulties. Simplifying the regimen and using fixed-dose combinations when appropriate can improve adherence.
Depression and anxiety are common after infarction and are associated with poorer quality of life and adherence. Screening and treatment of mood disorders are part of secondary prevention, not an element separate from cardiology. Cardiac rehabilitation provides a particularly suitable setting for integrating exercise, education, psychological support, and lifestyle modification.

Annual influenza vaccination is recommended in patients with cardiovascular disease and has assumed particular importance in contemporary recommendations on acute coronary syndromes. Influenza infection can increase inflammation, metabolic demand, and thrombotic risk, promoting cardiovascular events. Vaccination is therefore a cardiovascular as well as infectious-disease preventive intervention.
Follow-up must be organized around measurable goals: LDL-C and non-HDL-C, blood pressure, HbA1c in patients with diabetes, weight and waist circumference when relevant, renal function, symptoms, functional capacity, smoking, and adherence. Monitoring should be more frequent after a treatment change or recent event and may become less frequent once goals are stably achieved.

Telemedicine and remote monitoring can improve access, drug titration, and continuity, but must be integrated with clinical visits when physical examination, ECG, imaging, or complex assessments are needed. Their greatest value is often organizational: they reduce therapeutic inertia and facilitate early identification of medication discontinuation, rising blood pressure, or recurrent symptoms.
The quality of ischemic heart disease treatment is ultimately measured by the ability to maintain a coherent strategy over time. The acute phase naturally receives great attention, but most preventive benefit accumulates in the subsequent months and years through permanent control of causal factors. Optimal therapy is therefore a longitudinal process that must adapt to disease evolution without losing the pillars of secondary prevention.

Blood pressure control, diabetes, obesity, and cardiorenal protection

Arterial hypertension increases myocardial demand, wall stress, and the risk of atherosclerotic progression. In patients with coronary artery disease, treatment must reduce risk without excessively compromising perfusion pressure, especially in frail older adults or patients with critical stenoses and symptoms caused by hypotension. ACE inhibitors, ARBs, calcium channel blockers, beta-blockers, and diuretics are selected on the basis of comorbidities and concomitant indications. The optimal blood pressure is therefore an individualized clinical goal, not an isolated number applied without considering tolerability.
ACE inhibitors and ARBs are particularly useful when coronary artery disease is associated with diabetes, albuminuric kidney disease, hypertension, or ventricular dysfunction. The benefit does not derive from a direct antianginal effect, but from blood pressure reduction, neurohormonal modulation, and, in specific groups, cardiorenal protection. Creatinine and potassium must be checked after initiation or dose increases, recognizing that a modest initial rise in creatinine may be compatible with an expected hemodynamic effect.

In type 2 diabetes, cardiovascular treatment cannot be guided exclusively by HbA1c. GLP-1 receptor agonists and SGLT2 inhibitors with documented cardiovascular benefit should be considered independently of their glucose-lowering effect when justified by the clinical profile. GLP-1 agonists reduce weight and several atherosclerotic events; SGLT2 inhibitors have a particularly consistent effect on preventing heart failure and protecting the kidneys.
Drug selection must consider renal function, weight, hypoglycemia risk, heart failure, gastrointestinal disease, and preferences. Insulin and sulfonylureas may be necessary for glycemic control but do not have the same cardiovascular benefit profile as newer classes and increase the risk of hypoglycemia, an especially undesirable event in patients with coronary artery disease because of the adrenergic activation it may provoke.

Obesity is an independent therapeutic target. Weight loss improves blood pressure, blood glucose, sleep apnea, functional capacity, and quality of life. SELECT demonstrated that semaglutide 2.4 mg reduces major cardiovascular events in adults with overweight or obesity, established cardiovascular disease, and no diabetes; this result supports the concept that treating adiposity can directly modify cardiovascular prognosis and not merely surrogate factors.
Kidney disease and ischemic heart disease share numerous determinants. Blood pressure control, renin-angiotensin system blockade when indicated, and SGLT2 inhibitors can slow renal progression and reduce cardiac events. CKD, however, modifies the dose and safety of numerous antithrombotic and antianginal drugs; every treatment escalation must therefore be accompanied by review of renal function and interactions.

Pharmacological treatment of the acute phase beyond reperfusion

In acute coronary syndrome, reperfusion and antithrombotic therapy are central, but management also includes control of pain, oxygenation, blood pressure, heart rate, and congestion. Oxygen must not be given routinely to normoxemic patients because hyperoxia has not demonstrated benefit and may cause vasoconstriction. It is indicated when hypoxemia or respiratory failure is present according to the clinical picture.
Sublingual nitroglycerin can reduce ischemic pain and blood pressure in hemodynamically stable patients. Nitrates must be avoided in hypotension, suspected preload-dependent right ventricular infarction, and after recent use of PDE5 inhibitors. Symptomatic response must not delay ECG, troponin measurement, or reperfusion when indicated.

Morphine may be used for severe persistent uncontrolled pain, but is not routine anti-ischemic treatment. It can cause hypotension and nausea and delay the absorption of oral P2Y12 inhibitors; it should therefore be reserved for appropriate situations and used with awareness of pharmacokinetic interactions.
Beta-blockers can reduce ischemia and arrhythmias in selected patients, but early intravenous use is inappropriate in the presence of acute heart failure, low output, risk of shock, bradycardia, or conduction block. The acute phase therefore requires dynamic hemodynamic assessment; a drug useful in a stable patient may be harmful during shock or severe congestion.

Glycemia must be managed to avoid both marked hyperglycemia and iatrogenic hypoglycemia. Extremely intensive control strategies have not demonstrated a benefit sufficient to justify a high risk of hypoglycemia. In critically ill patients, the target is adapted to the situation and insulin is often the most controllable drug, while oral drugs may be temporarily stopped in the presence of instability, fasting, renal failure, or contrast procedures.
Pulmonary congestion requires diuretics and vasodilators when blood pressure permits; cardiogenic shock requires a different approach with urgent revascularization of the culprit vessel, vasoactive support, and assessment for mechanical support in selected cases. Therapy must be guided by perfusion and pressure, not rigid pharmacological protocols.

Secondary prevention must begin during hospitalization. A high-intensity statin, planning of combination lipid-lowering therapy when necessary, smoking counseling, diabetes assessment, influenza vaccination, and referral to cardiac rehabilitation should be arranged before discharge. The transition from hospital to community care is a phase at high risk of treatment interruptions and must be organized with a clear written plan.

Residual inflammation, colchicine, and limits of anti-inflammatory therapy

Atherosclerosis retains an inflammatory component even when LDL-C is very low. High-sensitivity C-reactive protein can identify residual inflammatory risk, but is not a test capable of locating an unstable plaque. CANTOS demonstrated that IL-1β inhibition can reduce events without changing lipids, providing causal proof of principle; however, canakinumab has not become routine cardiovascular therapy because of cost, infection risk, and its overall profile.
Low-dose colchicine has provided a more practicable strategy. COLCOT and LoDoCo2 demonstrated a reduction in events after infarction and in chronic coronary artery disease. European guidelines consider its use in selected patients with coronary atherosclerosis, especially when residual risk remains high despite standard therapy.

Its use is not without limitations. Colchicine is eliminated through pathways involving CYP3A4 and P-glycoprotein and can interact with potent inhibitors, increasing the risk of toxicity. Renal or hepatic failure, cytopenias, gastrointestinal disorders, and the risk of myopathy require attention. Therapy must therefore be prescribed after assessment of the overall pharmacological profile.
Anti-inflammatory therapy does not replace lipoprotein reduction. Lipids and inflammation are interconnected but distinct mechanisms, and the greatest benefit derives from simultaneous control of the principal determinants. A patient with elevated hs-CRP and LDL-C above target should receive adequate lipid-lowering therapy as a priority; residual inflammation becomes an additional target after the pillars of prevention have been implemented.

Follow-up after acute coronary syndrome and revascularization

The first weeks after an acute coronary syndrome are a phase of high residual risk. Early follow-up serves to assess symptoms, blood pressure, heart rate, adherence to DAPT, tolerance of lipid-lowering therapy, renal function, and the development of heart failure. A late visit after many months may miss the opportunity to correct persistently high LDL-C, hypotension from polypharmacy, or discontinuation of antiplatelet agents early.
The lipid profile must be rechecked after therapy is started or intensified within an interval short enough to permit further escalation if the target has not been reached. In a very-high-risk patient, therapeutic inertia is an avoidable cause of residual exposure. The goal is not simply to document a percentage improvement, but to reach and maintain the appropriate targets.

Ventricular function must be reassessed in patients with reduced LVEF after infarction because recovery following reperfusion and therapy may change the indication for an ICD or CRT. Assessment that is too early may overestimate permanent dysfunction; assessment that is too late may leave the patient without indicated protection against sudden death.
After PCI, recurrent angina must not automatically be attributed to restenosis. Progression of other lesions, vasospasm, microvascular dysfunction, anemia, and noncardiac causes are common. Tests and imaging must be selected on the basis of the clinical picture and not performed routinely in every asymptomatic patient.

After CABG, follow-up must include aggressive prevention of atherosclerosis in the native vessels and vein grafts. The absence of symptoms does not justify abandoning statins or antiplatelet agents. Cardiac rehabilitation and functional recovery have a particular role in the postoperative period, especially in older and deconditioned patients.
The transition to chronic management must conclude with a plan specifying which drugs are temporary and which are permanent, the expected duration of DAPT, lipid and blood pressure goals, laboratory monitoring, and signs requiring urgent assessment. A substantial proportion of avoidable events results from misunderstandings during this phase, especially when therapies prescribed during hospitalization are modified without coordination.